Results 31 to 40 of about 2,933 (228)
What makes gouty inflammation so variable? [PDF]
, 2017 Acute gout arthritis flares contribute dominantly to gout-specific impaired health-related quality of life, representing a progressively increasing public health problem.
Terkeltaub, Robert
core +2 more sources
Benzbromarone, Quercetin, and Folic Acid Inhibit Amylin Aggregation [PDF]
, 2016 Human Amylin, or islet amyloid polypeptide (hIAPP), is a small hormone secreted by pancreatic-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus.
Carrodeguas Villar, José Alberto +6 more
core +3 more sources
Guidelines for the treatment of gout: a Swiss perspective. [PDF]
, 2016 Gout is a common condition and its management is suboptimal. A number of guidelines on the management of gout have been published in the last decade by professional societies with the aim of informing the physician of the recommended therapeutic ...
Alromaih, F., So, A., Wüthrich, H.
core +1 more source
Scientific Reports, 2017 Gout is caused by elevated serum urate levels, which can be treated using inhibitors of the uric acid transporter, URAT1. Here, we characterize verinurad (RDEA3170), which is currently under evaluation for gout therapy.
Philip K. Tan +3 more
doaj +1 more source
The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone.
PLoS ONE, 2012 Eyes Absents (EYA) are multifunctional proteins best known for their role in organogenesis. There is accumulating evidence that overexpression of EYAs in breast and ovarian cancers, and in malignant peripheral nerve sheath tumors, correlates with tumor ...
Emmanuel Tadjuidje +5 more
doaj +1 more source
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF [PDF]
, 2017 Aims: Elevated serum uric acid concentration (SUA) has been associated with an increased risk of cardiovascular disease, but this may be due to unmeasured confounders.
Chen, Chen-Huan +16 more
core +3 more sources
Počki, 2018 Background. Renal damage is an almost constant symptom of gout, which determines the prognosis of the disease. Hyperuricemia in gouty nephropathy belongs to independent risk factors for deterioration of the nitrogen and electrolyte excretory function of
D.D. Ivanov +3 more
doaj +1 more source
BMC Complementary and Alternative Medicine, 2019 Background Prolonged hyperuricemia is associated with kidney disease or gouty arthritis. Whether Yokuininto, a commercially available Kampo medicine that has been used for osteoarthritis or rheumatoid arthritis, can exhibit anti-hyperuricemic and ...
Seung Hoon Lee +4 more
doaj +1 more source
Journal of the Science of Food and Agriculture, Volume 105, Issue 5, Page 2765-2776, 30 March 2025.Abstract BACKGROUND Over the past two decades, the global incidence of gout has markedly increased, affecting people worldwide. Considering the side effects of xanthine oxidase (XO) inhibitor drugs (e.g. allopurinol and febuxostat) used in the treatment of hyperuricemia and gout, the potential application of phytochemicals has been widely studied.
Tímea Bencsik +6 more
wiley +1 more source
Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). [PDF]
, 2016 Determine the efficacy and safety of daily lesinurad (200 or 400 mg orally) added to allopurinol in patients with serum uric acid (sUA) above target in a 12-month, randomised, phase III trial.
Adler, S. +9 more
core +1 more source